SEARCHCOHORTpediatrics, nutrition

cohort·pediatrics, nutrition, clinical nutrition, clinical trial, observational study·PMC10139017

Innova 2020: A Follow-Up Study of the Fecal Microbiota of Infants Using a Novel Infant Formula between 6 Months and 12 Months of Age

International Journal of Molecular Sciences · 13 authors, 9 centres

AI SUMMARY

FIDELITY 100%

POPULATIONInfants from 6 to 12 months of age

INTERVENTIONNovel starting formula (INN) with specific ingredients including a thermally inactivated postbiotic.

COMPARISONStandard formula (STD) and exclusive breastfeeding (BF).

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This follow-up study in 210 infants compared the effects of a novel infant formula, a standard formula, and breastfeeding on gut microbiota from 6 to 12 months of age. The novel formula group exhibited a gut microbiota profile more similar to the breastfed group than the standard formula group.

Full summary

991 CHARS

This follow-up study assessed the impact of a novel infant formula (INN) on the intestinal microbiota of infants aged 6 to 12 months, comparing it to a standard formula (STD) and breastfeeding (BF). The study included 210 infants (70 per group). Microbiota was analyzed at 6 and 12 months. Key findings showed that at 6 months, the INN group had significantly lower Bacillota levels than the BF and STD groups, while alpha diversity in the INN and BF groups differed significantly from the STD group. At 12 months, Verrucomicrobiota was significantly lower in the STD group compared to the BF and INN groups. The INN group was more similar to the BF group based on a microbial signature analysis. Calprotectin was higher in the STD group at 6 months, and immunoglobulin A was lower in the STD group after 6 months. Both formulas had higher propionic acid than the BF group at 6 months. The results suggest the novel formula may promote a microbiota more similar to that of breastfed infants.

PICO

PPOPULATION

Infants from 6 to 12 months of age

IINTERVENTION

Novel starting formula (INN) with specific ingredients including a thermally inactivated postbiotic.

OOUTCOME

Fecal microbiota composition (e.g., phyla, genera, alpha diversity), short-chain fatty acids, calprotectin, immunoglobulin A, and in silico metabolic pathways.

STUDY TYPE

cohort

SPECIALTY

pediatrics

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10139017

Innova 2020: A Follow-Up Study of the Fecal Microbiota of Infants Using a Novel Infant Formula between 6 Months and 12 Months of Age

International Journal of Molecular Sciences

READ THE FULL PAPER

ABSTRACT

The World Health Organization recommends exclusive breastfeeding on demand until at least the sixth month of life. Breast milk or infant formula is the infant’s primary food source until the age of one year, followed by the gradual introduction of other foods. During weaning, the intestinal microbiota evolves to a profile close to that of the adult, and its disruption can result in an increased incidence of acute infectious diseases. We aimed to determine whether a novel starting formula (INN) provides gut microbiota compositions more similar to those of breastfed (BF) infants from 6 to 12 months of age compared to a standard formula (STD). This study included 210 infants (70 per group) who completed the intervention until they reached the age of 12 months. In the intervention period, infants were divided into three groups. Group 1 received an INN formula with a lower protein content, a casein to whey protein ratio of approximately 70/30, twice as much docosahexaenoic acid as the STD formula, a thermally inactivated postbiotic ( Bifidobacterium animalis subsp. lactis , BPL1 TM HT), and twice as much arachidonic acid as the STD formula contained. The second group received the STD formula, while the third group was exclusively BF for exploratory purposes. In the course of the study, visits were conducted at 6 months and 12 months of age. Compared to the BF and STD groups, the Bacillota phylum levels in the INN group were significantly reduced after 6 months. At the end of 6 months, the alpha diversity indices of the BF and INN groups differed significantly from those of the STD group. At 12 months, the Verrucomicrobiota phylum levels in the STD group were significantly lower than those in the BF and INN groups. Based on the comparison between 6 and 12 months, the Bacteroidota phylum levels in the BF group were significantly higher than those in the INN and STD groups. When comparing the INN group with the BF and STD groups, Clostridium sensu stricto 1 was significantly higher in the INN group. The STD group had higher levels of calprotectin than the INN and BF groups at 6 months. The immunoglobulin A levels in the STD group were significantly lower than those in the INN and BF groups after 6 months. Both formulas had significantly higher levels of propionic acid than the BF group at 6 months. At 6 months, the STD group showed a higher quantification of all metabolic pathways than the BF group. The INN formula group exhibited similar behavior to the BF group, except for the superpathway of phospholipid biosynthesis ( E. coli ). We hypothesize that the novel INN formula may promote an intestinal microbiota that is more similar to the microbiota of an infant who consumes only human milk before the weaning period.

CITATION EXPORT

Julio Plaza-Diaz, Francisco Javier Ruiz-Ojeda, Javier Morales et al.. Innova 2020: A Follow-Up Study of the Fecal Microbiota of Infants Using a Novel Infant Formula between 6 Months and 12 Months of Age. International Journal of Molecular Sciences. (2023). https://doi.org/10.3390/ijms24087392

AUTHORS

13 · 9 CENTRES

Julio Plaza-Diaz, Francisco Javier Ruiz-Ojeda, Javier Morales, Rafael Martín-Masot, Eric Climent, Ángela Silva, Juan F. Martinez-Blanch, María Enrique, Marta Tortajada, Daniel Ramon, Beatriz Alvarez, Empar Chenoll, Ángel Gil

1Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain
2Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de Granada, 18014 Granada, Spain
3Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada
4RG Adipocytes and Metabolism, Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Center Munich, Neuherberg, 85764 Munich, Germany
5Institute of Nutrition and Food Technology “José Mataix”, Centre of Biomedical Research, University of Granada, Avda. del Conocimiento s/n. Armilla, 18016 Granada, Spain
6Product Development Department, Alter Farmacia SA, 28880 Madrid, Spain
7Pediatric Gastroenterology and Nutrition Unit, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain
8ADM-BIOPOLIS, Scientific Park Universitat de València, 46980 València, Spain
9CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, 28029 Madrid, Spain

EDITOR / REVIEWER

Abdelali Daddaoua